Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
188.88(c)
190.34(c)
193.84(c)
210.04(c)
199.88(c)
Last
2 716 841
2 072 202
1 733 424
2 723 891
4 004 905
Volume
-2.55% +0.77% +1.84% +8.36% -4.84% Change
Sales 2020
2,60 M - -
Net income 2020
-330 M - -
Net cash position 2020
1 213 M - -
P/E ratio 2020
-39,9x
Yield 2020
-
Sales 2021
14,3 M - -
Net income 2021
-383 M - -
Net cash position 2021
1 037 M - -
P/E ratio 2021
-37,6x
Yield 2021
-
Capitalization
14 233 M 14 233 M -
EV / Sales 2020
5 008x
EV / Sales 2021
920x
Nbr of Employees
304
Free-Float
82,8%
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic...
Notations Surperformance© of CRISPR Therapeutics AG
Trading Rating : Investor Rating :
All news about CRISPR THERAPEUTICS AG
News in other languages on CRISPR THERAPEUTICS AG
Analyst Recommendations on CRISPR THERAPEUTICS AG
Chart CRISPR THERAPEUTICS AG
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CRISPR THERAPEUTICS AG
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
18
Average target price
146,56 $
Last Close Price
199,88 $
Spread / Highest target
5,06%
Spread / Average Target
-26,7%
Spread / Lowest Target
-77,5%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
